Nuropod, the wearable neurotechnology brand owned by Parasym, has announced a short online assessment designed to help adults experiencing daily stress understand their vagus nerve health, producing a personal nervous system score across 10 areas that include fatigue, sleep, and digestion.
-- Nuropod, the wearable neurotechnology brand owned by Parasym, has announced its nervous system impairment assessment for stressed adults, a short online questionnaire that produces a personal nervous system health score.
More information is available at https://nuropod.com/pages/nervous-system-impairment-assessment
The announcement comes as many adults report that everyday stress is affecting their sleep, energy, and mood. Nuropod's quick assessment covers these same areas, aiming to help people under ongoing strain better understand their stress response and its relationship to vagus nerve health.
The assessment takes less than five minutes and covers 10 key areas of well-being, including fatigue, sleep, and digestion. Developed by Dr. Elisabetta Burchi and Dr. Greta Dalle Luche of Parasym and based on peer-reviewed research, it addresses questions such as why sleep is disrupted at night, why low mood lingers, why digestion is erratic, and whether burnout may be building. Responses generate a personalized score with insights across all areas.
The assessment is informational and is not a diagnostic tool. It does not replace guidance from a qualified health professional, and anyone with ongoing health concerns is encouraged to speak with their healthcare provider.
Alongside the score, participants receive information about targeted vagus nerve stimulation with Nuropod, a wearable device designed to support nervous system health. Its earpiece clips onto the tragus, the part of the outer ear just in front of the ear canal, where the vagus nerve reaches the skin, and delivers gentle electrical pulses using AVNT™, Parasym's proprietary waveform. Most people use the device for around 30 minutes, once or twice a day, while working, reading, or watching television, with no surgery, clinic visit, gel, or prescription required.
Nuropod is backed by 60+ completed clinical studies, 100+ ongoing clinical studies, 150+ research partners, and 10+ years of research and development. Classified by the FDA as a non-significant risk device, it has recorded an average 35% reduction in anxious thoughts across study participants.
Additional information about Nuropod and the nervous system assessment is available at https://nuropod.com/
Disclaimer: Research referenced in this article was conducted using Parasym's neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.
Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/
Source: PressCable
Release ID: 89205384
In case of encountering any inaccuracies, problems, or queries arising from the content shared in this press release that necessitate action, or if you require assistance with a press release takedown, we urge you to notify us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be readily available to promptly address your concerns within 8 hours, resolving any identified issues diligently or guiding you through the necessary steps for removal. The provision of accurate and dependable information is our primary focus.